Citius Pharmaceuticals Inc., a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, has received $2.4 million in non-dilutive capital through New Jersey’s Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss (NOL) Program, funded through the New Jersey Economic Development Authority (NJEDA).   The NOL Program enables participants to sell their New Jersey net operati...